Logo image of SAN.PA

SANOFI (SAN.PA) Stock Price, Forecast & Analysis

Europe - Euronext Paris - EPA:SAN - FR0000120578 - Common Stock

77.54 EUR
-2.21 (-2.77%)
Last: 1/28/2026, 7:00:00 PM

SAN.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap187.28B
Revenue(TTM)66.91B
Net Income(TTM)13.80B
Shares2.42B
Float2.16B
52 Week High110.88
52 Week Low76.15
Yearly Dividend3.79
Dividend Yield0%
EPS(TTM)7.6
PE10.2
Fwd PE9.17
Earnings (Next)01-29
IPO2002-07-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
SAN.PA short term performance overview.The bars show the price performance of SAN.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -2 -4 -6 -8 -10

SAN.PA long term performance overview.The bars show the price performance of SAN.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of SAN.PA is 77.54 EUR. In the past month the price decreased by -6.58%. In the past year, price decreased by -25.73%.

SANOFI / SAN Daily stock chart

SAN.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SAN.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to SAN.PA. While SAN.PA is still in line with the averages on profitability rating, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SAN.PA Financial Highlights

Over the last trailing twelve months SAN.PA reported a non-GAAP Earnings per Share(EPS) of 7.6. The EPS decreased by -5.35% compared to the year before.


Industry RankSector Rank
PM (TTM) 20.63%
ROA 10.63%
ROE 18.84%
Debt/Equity 0.18
Chartmill High Growth Momentum
EPS Q2Q%1.75%
Sales Q2Q%-7.47%
EPS 1Y (TTM)-5.35%
Revenue 1Y (TTM)2.56%

SAN.PA Forecast & Estimates

29 analysts have analysed SAN.PA and the average price target is 101.26 EUR. This implies a price increase of 30.58% is expected in the next year compared to the current price of 77.54.

For the next year, analysts expect an EPS growth of 2.24% and a revenue growth -0.09% for SAN.PA


Analysts
Analysts79.31
Price Target101.26 (30.59%)
EPS Next Y2.24%
Revenue Next Year-0.09%

SAN.PA Ownership

Ownership
Inst Owners46.74%
Ins Owners0.01%
Short Float %N/A
Short RatioN/A

About SAN.PA

Company Profile

SAN logo image Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Company Info

SANOFI

46 Avenue de la Grande Armee

Paris ILE-DE-FRANCE FR

Employees: 82878

SAN Company Website

SAN Investor Relations

Phone: 33153774000

SANOFI / SAN.PA FAQ

Can you describe the business of SANOFI?

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.


Can you provide the latest stock price for SANOFI?

The current stock price of SAN.PA is 77.54 EUR. The price decreased by -2.77% in the last trading session.


What is the dividend status of SANOFI?

SAN.PA does not pay a dividend.


What is the ChartMill rating of SANOFI stock?

SAN.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Can you provide the sector and industry classification for SANOFI?

SANOFI (SAN.PA) operates in the Health Care sector and the Pharmaceuticals industry.


What is the employee count for SAN stock?

SANOFI (SAN.PA) currently has 82878 employees.


What is the next earnings date for SAN stock?

SANOFI (SAN.PA) will report earnings on 2026-01-29, before the market open.